Investor profile
Perry Nisen
Corporate VC, Private equity, Venture capital & Executive Partner/Advisor at Sofinnova Investments, Independent Director, Chair of Science and Technology at Teva Pharmaceuticals
Perry Nisen is an Independent Director, Chair of Science and Technology at Teva Pharmaceuticals, whose known portfolio counts 10 companies.
Is Perry Nisen a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- HealthcareSaaS
- Focus
- BiosimilarsBiotechCell TherapyDrug DiscoveryLife ScienceMedical DevicesPharmaRNA TherapeuticsTelecommunicationsTherapeutics
Contacts
Affiliated funds' portfolios
Executive Partner/Advisor at Sofinnova Investments, whose known portfolio counts 9 companies
- Star Therapeutics
- Aeovian Pharmaceuticals
- Avenzo Therapeutics
- Atsena Therapeutics
- Axonis Therapeutics
- Edgewise Therapeutics
- Expedition Therapeutics
- Coultreon Biopharma
- ARTBIO
Independent Director, Chair of Science and Technology at Teva Pharmaceuticals, whose known portfolio counts 10 companies
- Gamida Cell
- BiolineRx
- Heptares Therapeutics
- Wave Life Sciences
- Cocrystal Discovery
- Ignyta
- MicroCHIPS
- NeuroGen Pharma
- Proneuron Biotechnologies
- TransPharma Medical
Investor Profile
Perry Nisen is listed against sectors Healthcare and SaaS, and focus areas Biosimilars, Biotech, Cell Therapy and Drug Discovery in the database.
Stage-wise, the deals at Teva Pharmaceuticals cluster around Growth, Late-Stage and Seed rounds.
The firm portfolio and the focus above give founders context on whether Perry Nisen matches their raise.
Colleagues
Tim Bliss
Investor Relations & Finance
United States
Zeev Zehavi
Vice President
Petah Tikva, Israel
Agnieszka Fordonska
Country Manager Poland w Centerscape Investments Poland
Warsaw, Poland
Yarden Sheffi
Financial Storyteller
Tel Aviv-Yafo, Israel
Naomi Pacalin
Investor
San Francisco, United States
Nathalie Auber
Partner and CFO
San Francisco, United States
Lars Ekman
Excecutive Partner
San Diego, United States
Raymond Bower
Portfolio Manager of the Synergy Fund
Seattle, United States
Erika Lakos
Head ef Technical and Investment Department
Hungary
Alain Azan
President
San Francisco, United States
Maha Katabi
General Partner
Canada
David Kabakoff
Executive Partner
Rancho Santa Fe, United States
Jonathan Leff
Executive Partner
Menlo Park, United States
Frequently asked questions
Who is Perry Nisen?
Perry Nisen is a corporate venture investor and private equity investor based in San Diego, California, United States, listed as Independent Director, Chair of Science and Technology at Teva Pharmaceuticals. The known portfolio of that firm counts 10 companies. That portfolio belongs to the firm, not to Perry Nisen personally.
What does Perry Nisen invest in?
Listed sectors include Healthcare and SaaS; listed focus areas include Biosimilars, Biotech, Cell Therapy and Drug Discovery. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Perry Nisen invest at?
Teva Pharmaceuticals appears in Growth, Late-Stage and Seed rounds across its known deals, and Perry Nisen is listed there as Independent Director, Chair of Science and Technology. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Perry Nisen listed at?
Perry Nisen is listed as Independent Director, Chair of Science and Technology at Teva Pharmaceuticals. 13 other people in the database share a firm with Perry Nisen.
How do I contact Perry Nisen?
An email address, a phone number and a LinkedIn page are on file for Perry Nisen. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal